MDA vs MDMA: What's the Difference Between Sally and Molly?

MDA (3,4-methylenedioxyamphetamine, street name “Sally”) and MDMA (3,4-methylenedioxymethamphetamine, “Molly”) are closely related compounds that are frequently confused or conflated — but they are pharmacologically distinct in ways that matter for harm reduction. MDA produces more pronounced hallucinogenic and visual effects than MDMA, lasts significantly longer, and animal research indicates it may be more neurotoxic at equivalent doses. The two compounds cannot be told apart by appearance, and Marquis reagent cannot distinguish them — but Simon’s reagent can.

Quick answers

What is MDA (Sally)? MDA is 3,4-methylenedioxyamphetamine, the structural precursor to MDMA. The key chemical difference is that MDMA has an N-methyl group that MDA lacks. This small change produces meaningfully different pharmacology and subjective effects.

Is MDA stronger than MDMA? Not simply stronger — different. MDA is more hallucinogenic and visually active; MDMA is more empathogenic and entactogenic. MDA’s effects last longer (roughly 8–12 hours vs. 4–6 hours for MDMA) and it is somewhat more potent by weight. Typical MDA doses run 80–120 mg; MDMA doses typically run 75–125 mg.

Can a test kit distinguish MDA from MDMA? Yes — but only Simon’s reagent. Both MDA and MDMA turn Marquis reagent purple-black, making it useless for distinguishing them. Simon’s reagent turns blue in the presence of MDMA (a secondary amine) and produces no blue color change with MDA (a primary amine). This is the key differentiator.

Is MDA in ecstasy pills? Yes. A 25-year analysis of 4,719 submitted samples found only 48% contained pure MDMA — 52% were misrepresented, with 199 distinct adulterants detected (PMID 39437494). MDA appears in a meaningful subset of those samples.

Is MDA more dangerous than MDMA? Animal studies show MDA causes greater serotonin terminal damage than MDMA at equivalent doses (PMID 2457659). Controlled human data on MDA specifically is very limited. The longer duration also changes the redosing math significantly.

MDA vs MDMA at a glance

What MDA is and how it differs chemically

MDA and MDMA are both substituted amphetamines in the methylenedioxy family. The structural difference is a single N-methyl group: MDMA has it, MDA does not. That group makes MDMA a secondary amine and MDA a primary amine — a distinction that turns out to matter for both pharmacology and drug testing.

Both compounds were synthesized in the early 20th century and both were investigated for therapeutic uses before becoming controlled substances. MDA predates MDMA and was explored as an adjunct to psychotherapy in the 1960s and 70s, partly because of its psychedelic character.

How MDA and MDMA work differently

Both drugs act primarily by reversing monoamine transporters — forcing the release of serotonin, dopamine, and norepinephrine from nerve terminals rather than reuptaking them. In this sense they are mechanistically similar. The key pharmacological difference is what else MDA does.

MDA has greater functional activity at 5-HT2A serotonin receptors — the same receptors that classic psychedelics like LSD and psilocybin activate. In animal models, MDA produces more hallucinogen-like behavioral responses (head-twitch response, a reliable proxy for 5-HT2A agonism) than MDMA. Binding studies show both compounds have only weak affinity at 5-HT2A in absolute terms — around 3,000–15,000 nM depending on stereoisomer and assay — but MDA’s greater functional activity at this receptor explains its more pronounced visual and perceptual effects in humans (PMID 2871581, PMID 24142203).

At the serotonin transporter (SERT), both drugs cause comparable serotonin release. A 1986 study directly comparing the enantiomers of MDA and MDMA found similar serotonin-releasing potency at the transporter level, but with a notable difference: the N-methylation in MDMA reduces dopamine-releasing potency compared to MDA (PMID 2880735). MDA’s relatively greater dopaminergic activity contributes to its more stimulating, driven character.

The practical summary: MDA = more visual, more stimulating, more psychedelic. MDMA = more empathogenic, more “loved-up,” less hallucinogenic.

Duration and pharmacokinetics

MDA lasts substantially longer than MDMA. Controlled human pharmacokinetic studies measuring MDA as a metabolite of MDMA — the closest available data — found MDA has a half-life of 10.6–12.3 hours, compared to roughly 7–8 hours for MDMA itself (PMID 18520604). When MDA is taken directly as the parent drug, the active duration in most users is reported at approximately 8–12 hours, compared to MDMA’s typical 4–6 hours.

This longer duration has direct harm reduction implications. The redosing window for MDA is different: a second dose taken at what would be a typical MDMA redosing interval (90–120 minutes) arrives long before the first MDA dose has cleared. The extended duration also means adverse effects — cardiovascular strain, hyperthermia, jaw clenching — persist for longer.

MDMA is metabolized to MDA inside your body

When MDMA is taken, a small fraction is converted to MDA in the liver via N-demethylation — roughly 3–5% of the administered dose (PMID 15228154). This means that after taking MDMA, MDA is detectable in blood and urine even if no MDA was consumed directly.

This metabolic conversion has two implications: (1) every MDMA experience involves some MDA exposure, and (2) after a second dose of MDMA, the already-impaired CYP2D6 enzyme produces disproportionately higher MDA concentrations — one controlled study found MDA levels climbed sharply with repeated dosing (PMID 15071716).

Neurotoxicity: what the animal data shows

Animal studies consistently show that both MDA and MDMA damage serotonergic nerve terminals in the brain — and that MDA appears to cause greater damage than MDMA at equivalent doses. A 1988 immunocytochemical study directly comparing the two compounds found that both produced selective ablation of serotonin axons throughout the forebrain, but MDA caused a larger reduction in 5-HT axon density than MDMA at the same dosage (PMID 2457659). MDA’s neurotoxicity in the rodent brain was first characterized in 1985 (PMID 4023719).

Critical dose caveat — these numbers are not comparable to human recreational use. The animal studies used 20 mg/kg subcutaneous injection, twice daily for four days. Scaled to a 70 kg human, this is roughly 230 mg per dose, injected, administered four times daily — far exceeding a typical single oral recreational dose of 80–120 mg. Injected drugs also produce much higher peak plasma concentrations than oral administration. These studies establish a mechanism and a relative comparison (MDA ≥ MDMA for neurotoxic potential), but cannot be read as evidence that recreational oral MDA at typical doses causes the damage seen in rodents.

There are no controlled human studies specifically assessing MDA neurotoxicity in isolation. The human neurotoxicity literature on MDMA — already complicated by heavy-user sampling bias and polydrug confounding — has no equivalent for MDA. What the animal data does establish is that if MDMA carries neurotoxic risk at sufficient doses, MDA carries at least equivalent and likely greater risk.

Testing: the only way to tell them apart

Marquis reagent: Both MDA and MDMA turn purple-black. This test confirms the presence of a methylenedioxyamphetamine compound but cannot distinguish which one.

Simon’s reagent: This is the differentiator. Simon’s reagent reacts specifically with secondary amines — compounds with an N-methyl or similar substituent. MDMA is a secondary amine and turns blue. MDA is a primary amine and produces no blue color change. If you have a sample that goes purple-black with Marquis but does not turn blue with Simon’s, you likely have MDA rather than MDMA.

Practical implication: Testing with Marquis alone tells you it’s in the methylenedioxy family. Testing with both Marquis and Simon’s tells you which compound you have. A DanceSafe complete testing kit includes Simon’s reagent alongside Marquis, Mecke, and fentanyl test strips — the combination gives you the most information about an unknown sample. See our drug testing guide for step-by-step technique.

MDA in the pill supply

Pills or powders sold as MDMA sometimes contain MDA instead of, or in addition to, MDMA. A 25-year analysis of samples submitted to EcstasyData found that only 48% of samples contained pure MDMA, with the remainder misrepresented in some way (PMID 39437494). The dataset identified 199 distinct adulterants across 4,719 submitted samples.

One important caveat: EcstasyData samples are submitted by users who often already suspect something is wrong with their product. Adulteration rates in this dataset likely overestimate rates in the broader drug supply. That said, the Simon’s reagent test provides a practical and inexpensive way to confirm whether a sample is MDMA or MDA before use.

Harm reduction summary

• Duration: MDA lasts roughly twice as long as MDMA. Plan accordingly — an 8-12 hour experience is a full day commitment.
• Redosing: Harm reduction guidelines already caution against redosing MDMA; those cautions are stronger for MDA given its longer half-life and potentially greater neurotoxic profile.
• Testing: Marquis alone is not sufficient. Use Simon’s reagent to determine whether a sample is MDA or MDMA before deciding on dose timing.
• Hyperthermia risk: MDA’s greater stimulant properties and extended duration mean thermoregulation demands attention for longer. The same principles apply as with MDMA — cool environments, rest breaks, controlled hydration.
• Set and setting: MDA’s more prominent visual and psychedelic character means the experience is less predictable than MDMA for people expecting a purely empathogenic effect. Treating it more like a psychedelic in terms of preparation is reasonable.

For a full breakdown of MDMA risks, dosing, and the supplement protocol, see our MDMA harm reduction guide. For specific drug combinations, see the interaction checker.

Sources: PMID 2871581 | PMID 24142203 | PMID 2880735 | PMID 18520604 | PMID 15228154 | PMID 15071716 | PMID 10671903 | PMID 2457659 | PMID 2443644 | PMID 4023719 | PMID 39437494